Evidence map›Paper›PMID 38027128›Full record

ArticleFrontiers in endocrinology2023

How patients experience thyroid eye disease.

Terry J Smith, Laszlo Hegedüs, Ira Lesser, Petros Perros, Kimberly Dorris, Michele Kinrade, Patti Troy-Ott, Laura Wuerth, Mukund Nori

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Diagnostic methods for managing dry eyes.World journal of methodology · 2025
    Article
  10. Article
  11. Review
  12. The Use of Biologics for Thyroid Eye Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Terry J SmithKellogg Eye Center, Department of Ophthalmology and Visual Sciences and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, United States.
Laszlo HegedüsDepartment of Endocrinology, Odense University Hospital, Odense, Denmark.
Ira LesserDepartment of Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, United States.
Petros PerrosInstitute of Translational and Clinical Research, Newcastle University, Newcastle upon Tyne, United Kingdom.
Kimberly DorrisGraves' Disease and Thyroid Foundation, Rancho Santa Fe, CA, United States.
Michele KinradeScientific Solutions, RareLife Solutions, Inc., Westport, CT, United States.
Patti Troy-OttScientific Solutions, RareLife Solutions, Inc., Westport, CT, United States.
Laura WuerthScientific Solutions, RareLife Solutions, Inc., Westport, CT, United States.
Mukund NoriScientific Solutions, RareLife Solutions, Inc., Westport, CT, United States.
Scientific Solutions (United States) · USNewcastle University · GBOdense University Hospital · DKUCLA Medical Center · USUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To determine the impact of thyroid eye disease (TED) on patients in various stages of the disease. Background: TED is a debilitating and potentially sight-threatening inflammatory autoimmune disease that is frequently misdiagnosed. Challenging quality-of-life (QoL) issues can persist long after the active phase of disease has subsided. Methods: A 62-question survey was designed as a hypothesis-generating instrument to identify key issues confronting patients ≥18 years old with physician-diagnosed TED. Questions focused primarily on physical and emotional status, and QoL experiences in the 2 months prior to the survey. Data for individual questions are presented as summary statistics. Correlations between questions were determined using χ Results: The 443 respondents were 18 to >80 years old; >90% female, and >80% from the United States. Time since TED diagnosis ranged from <1 year to >10 years. Participants provided >500 free-form responses describing experiences of living with TED. Physical signs/symptoms were experienced by 307/443 (69%) patients. Of those responding to the QoL questions (N = 394), 53 (13%) reported symptoms improving, 73 (19%) reported symptoms worsening, and 255 (65%) reported no change in the 2 months prior to the survey. The most bothersome signs/symptoms were dry/gritty eyes, light sensitivity, bulging eyes, and pressure or pain behind the eyes. Respondents <60 years were significantly (p < 0.0001) more likely to report symptomatic TED than older patients. Of 394 respondents, 179 (45%) reported feeling depressed and/or anxious, 174 (44%) reported concern about their appearance, and 73 (19%) avoided public situations; 192 (49%) reported declines in confidence or feelings of general well-being, and 78 (20%) reported an inability to achieve goals. Activities limited by TED included reading, driving, and socializing. The proportion of respondents experiencing these negative QoL measures was higher when patients reported experiencing >5 symptoms, had been diagnosed within the last 5 years, or were <60 years of age. Conclusions: Physical manifestations of TED impact QoL for patients through all phases of the disease. It is essential that physicians and healthcare professionals become more familiar with patient experiences such as those described here to better help patients manage their disease.

Indexed as

Autoimmune DiseasesGraves OphthalmopathyAdolescentAged, 80 and overEmotionsFemaleHumansMaleQuality of LifeSurveys and Questionnairesactive diseasechronic diseaseGraves’ orbitopathypatient experiencepatient surveyquality of lifethyroid-associated ophthalmopathythyroid eye disease

Identifiers

PMID38027128
PMCPMC10665908
OpenAlexW4388636802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.